Literature DB >> 32409288

Analysis of Four Polymorphisms Located at the Promoter of the Estrogen Receptor Alpha ESR1 Gene in a Population With Gender Incongruence.

Rosa Fernández1, Enrique Delgado-Zayas2, Karla Ramírez2, Joselyn Cortés-Cortés2, Esther Gómez-Gil3, Isabel Esteva4, Mari Cruz Almaraz4, Antonio Guillamon5, Eduardo Pásaro2.   

Abstract

INTRODUCTION: Gender incongruence defines a state in which individuals feel discrepancy between the sex assigned at birth and their gender. Some of these people make a social transition from male to female (trans women) or from female to male (trans men). By contrast, the word cisgender describes a person whose gender identity is consistent with their sex assigned at birth. AIM: To analyze the implication of the estrogen receptor α gene (ESR1) in the genetic basis of gender incongruence. MAIN OUTCOME MEASURES: Polymorphisms rs9478245, rs3138774, rs2234693, rs9340799.
METHOD: We carried out the analysis of 4 polymorphisms located at the promoter of the ESR1 gene (C1 = rs9478245, C2 = rs3138774, C3 = rs2234693, and C4 = rs9340799) in a population of 273 trans women, 226 trans men, and 537 cis gender controls. For SNP polymorphisms, the allele and genotype frequencies were analyzed by χ2 test. The strength of the SNP associations with gender incongruence was measured by binary logistic regression. For the STR polymorphism, the mean number of repeats were analyzed by the Mann-Whitney U test. Measurement of linkage disequilibrium and haplotype frequencies were also performed.
RESULTS: The C2 median repeats were shorter in the trans men population. Genotypes S/S and S/L for the C2 polymorphism were overrepresented in the trans men group (P = .012 and P = .003 respectively). We also found overtransmission of the A/A genotype (C4) in the trans men population (P = .017), while the A/G genotype (C4) was subrepresented (P = .009]. The analyzed polymorphisms were in linkage disequilibrium. In the trans men population, the T(C1)-L(C2)-C(C3)-A(C4) haplotype was overrepresented (P = .019) while the T(C1)-L(C2)-C(C3)-G(C4) was subrepresented (P = .005).
CONCLUSION: The ESR1 is associated with gender incongruence in the trans men population. Fernández R, Delgado-Zayas E,RamírezK, et al. Analysis of Four Polymorphisms Located at the Promoter of the Estrogen Receptor Alpha ESR1 Gene in a Population With Gender Incongruence. Sex Med 2020;XX:XXX-XXX.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gender incongruence; rs2234693; rs3138774; rs9340799; rs9478245; transgender

Year:  2020        PMID: 32409288     DOI: 10.1016/j.esxm.2020.04.002

Source DB:  PubMed          Journal:  Sex Med        ISSN: 2050-1161            Impact factor:   2.491


  4 in total

Review 1.  Challenges in the care of transgender and gender-diverse youth: an endocrinologist's view.

Authors:  Stephen M Rosenthal
Journal:  Nat Rev Endocrinol       Date:  2021-08-10       Impact factor: 43.330

2.  Should chromosomal analysis be performed routinely during the baseline evaluation of the gender affirmation process? The outcomes of a large cohort of gender dysphoric individuals.

Authors:  Aysel Kalaycı Yigin; Şenol Turan; Mustafa Tarık Alay; Yasin Kavla; Öznur Demirel; Mehmet Seven
Journal:  Int J Impot Res       Date:  2022-05-17       Impact factor: 2.896

3.  Epigenetics Is Implicated in the Basis of Gender Incongruence: An Epigenome-Wide Association Analysis.

Authors:  Karla Ramirez; Rosa Fernández; Sarah Collet; Meltem Kiyar; Enrique Delgado-Zayas; Esther Gómez-Gil; Tibbert Van Den Eynde; Guy T'Sjoen; Antonio Guillamon; Sven C Mueller; Eduardo Pásaro
Journal:  Front Neurosci       Date:  2021-08-19       Impact factor: 4.677

4.  Association study of novel single nucleotide polymorphisms of androgen receptor and estrogen receptor-α genes with male infertility in Northwest of Iran: A case-control study.

Authors:  Elham Ghadirkhomi; Seyed Abdolhamid Angaji; Maryam Khosravi; Mohammad Reza Mashayekhi
Journal:  Int J Reprod Biomed       Date:  2022-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.